Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-122.53M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -26.08% |
| Return on Assets (Trailing 12 Months) | -24.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.15 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.15 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.10 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.37 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.22 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.79M |
| Free Float | 54.56M |
| Market Capitalization | $1.83B |
| Average Volume (Last 20 Days) | 1.20M |
| Beta (Past 60 Months) | -1.64 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.78% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |